New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the "Lipid Lurkers" Inside Their Arteries

Core Insights - The article discusses the launch of the "Lipid Lurkers" campaign by Esperion, aimed at educating patients about the risks associated with high LDL cholesterol and promoting their products NEXLETOL and NEXLIZET [1][13]. Group 1: Campaign Overview - The "Lipid Lurkers" campaign visually represents the dangers of high LDL cholesterol, helping patients understand its impact on their artery walls [1]. - The campaign was rated highly among patients with high LDL-C for its stopping power, impact, and motivation to consult healthcare providers about NEXLETOL and NEXLIZET [1][2]. - The campaign encourages patients to take control of their health by addressing their LDL cholesterol levels [15]. Group 2: Target Audience and Product Indications - The target audience includes U.S. adults diagnosed with high LDL-C who cannot take statins or have not achieved desired LDL-C levels despite statin therapy [2]. - The recent FDA label expansion for NEXLETOL and NEXLIZET allows these medications to be used for primary prevention in patients at risk for cardiovascular events, expanding the potential patient population to over 70 million in the U.S. [20]. Group 3: Clinical Evidence and Safety Information - The CLEAR Program aims to generate clinical evidence on the safety and efficacy of bempedoic acid, a key component of NEXLETOL and NEXLIZET, with over 60,000 participants expected [6]. - Common adverse reactions reported in clinical trials for bempedoic acid include upper respiratory tract infections, muscle spasms, and elevated liver enzymes [4][17]. - NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to their components, and serious reactions such as anaphylaxis have been reported [9].